Dynavax Technologies (DVAX) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/04/22
Dynavax Technologies (DVAX) Recently Broke Out Above the 50-Day Moving AverageZacks Investment Research • 10/25/22
Dynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 10/24/22
Does Dynavax Technologies (DVAX) Have the Potential to Rally 210% as Wall Street Analysts Expect?Zacks Investment Research • 10/21/22
Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022PRNewsWire • 10/20/22
Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual ConferencePRNewsWire • 10/14/22
Clover's Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated VaccineGlobeNewsWire • 09/19/22
Valneva and IDT Biologika Agree on Termination of their COVID-19 CollaborationGlobeNewsWire • 09/16/22
Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague VaccinePRNewsWire • 09/12/22
Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/08/22
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious DiseasesGlobeNewsWire • 09/06/22
Clover's COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated VaccineGlobeNewsWire • 09/05/22
Down 21.7% in 4 Weeks, Here's Why Dynavax Technologies (DVAX) Looks Ripe for a TurnaroundZacks Investment Research • 08/30/22
Clover's COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5GlobeNewsWire • 08/29/22
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001GlobeNewsWire • 08/29/22